Benign Prostatic Hyperplasia - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 124 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Benign Prostatic Hyperplasia - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Benign Prostatic Hyperplasia - Pipeline Review, H2 2014', provides an overview of the Benign Prostatic Hyperplasia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Benign Prostatic Hyperplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Benign Prostatic Hyperplasia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Benign Prostatic Hyperplasia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Benign Prostatic Hyperplasia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Benign Prostatic Hyperplasia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Benign Prostatic Hyperplasia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Benign Prostatic Hyperplasia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Benign Prostatic Hyperplasia Overview 10
Therapeutics Development 11
Pipeline Products for Benign Prostatic Hyperplasia - Overview 11
Pipeline Products for Benign Prostatic Hyperplasia - Comparative Analysis 12
Benign Prostatic Hyperplasia - Therapeutics under Development by Companies 13
Benign Prostatic Hyperplasia - Therapeutics under Investigation by Universities/Institutes 16
Benign Prostatic Hyperplasia - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Benign Prostatic Hyperplasia - Products under Development by Companies 20
Benign Prostatic Hyperplasia - Products under Investigation by Universities/Institutes 21
Benign Prostatic Hyperplasia - Companies Involved in Therapeutics Development 22
Euroscreen S.A. 22
Aphios Corporation 23
Astellas Pharma Inc. 24
Chong Kun Dang Pharmaceutical Corp. 25
Chugai Pharmaceutical Co., Ltd. 26
Ono Pharmaceutical Co., Ltd. 27
SK Chemicals Co., Ltd. 28
Addex Therapeutics Ltd 29
AEterna Zentaris Inc. 30
IntelGenx Corp. 31
Kaken Pharmaceutical Co., Ltd. 32
Nymox Pharmaceutical Corporation 33
Yungjin Pharm Ind. Co., Ltd. 34
Quest PharmaTech Inc. 35
Sophiris Bio, Inc. 36
AndroScience Corporation 37
AmVac AG 38
KAEL-GemVax Co., Ltd. 39
Ausio Pharmaceuticals, LLC 40
Biolab Sanus Farmaceutica Ltda. 41
Hanmi Pharmaceuticals, Co. Ltd. 42
SOM Biotech SL 43
Curadis GmbH 44
Mezzion Pharma Co. Ltd. 45
Benign Prostatic Hyperplasia - Therapeutics Assessment 46
Assessment by Monotherapy Products 46
Assessment by Combination Products 47
Assessment by Target 48
Assessment by Mechanism of Action 51
Assessment by Route of Administration 54
Assessment by Molecule Type 56
Drug Profiles 58
NX-1207 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
topsalysin - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
MCS-2 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
ozarelix - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
AUS-131 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
udenafil - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
AMV-110 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
ASP-4901 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
ESN-364 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
NCE-403 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
CKD-902 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
YOB-1604 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
YBH-1603 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
ADX-68692 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Sperol - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
tertomotide - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
ASC-JM.X2 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
SL-052 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
S-40542 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
SOM-2391 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
(tamsulosin + dutasteride) - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
CH-5036249 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
INT-0031 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Synthetic Peptide for Oncology and Male health - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Synthetic Peptide to Target GPR54 for Womens Health, Male Health and Oncology - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
CR-1493 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
SOM-2393 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
BL-214 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
ONO-8430506 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Small Molecules to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Benign Prostatic Hyperplasia - Recent Pipeline Updates 96
Benign Prostatic Hyperplasia - Dormant Projects 112
Benign Prostatic Hyperplasia - Discontinued Products 113
Benign Prostatic Hyperplasia - Product Development Milestones 114
Featured News & Press Releases 114
Sep 02, 2014: Sophiris Bio Reports Completion of Enrollment in the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia 114
Jul 22, 2014: Nymox Announces Positive Efficacy Results in Phase 3 Repeat Injection Trial of NX-1207 for BPH 114
Jul 15, 2014: Nymox Announces Completion of Enrollment for Second BPH Re-Injection Study 115
Jun 17, 2014: Nymox Reports Positive Update on Nerve Sparing and Sexual Function Preservation in Men Treated With NX-1207 115
Jun 11, 2014: Nymox Reports Positive New Safety Study Data for Phase 3 BPH Drug 116
May 08, 2014: Nymox Announces Completion of Second Pivotal Phase 3 NX-1207 Trial for BPH 117
Nov 19, 2013: Cialis (tadalafil) marks 10 years since U.S. approval 118
Nov 11, 2013: Nymox Reports Update and Positive Safety Data for Phase 3 NX02-0022 Reinjection Study of NX-1207 for BPH 119
Oct 28, 2013: Sophiris Announces First Patients Dosed in the PLUS-1 Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia 120
Oct 25, 2013: FDA Approves Addition to CIALIS Product Label 120
Appendix 122
Methodology 122
Coverage 122
Secondary Research 122
Primary Research 122
Expert Panel Validation 122
Contact Us 123
Disclaimer 123

List of Tables
Number of Products under Development for Benign Prostatic Hyperplasia, H2 2014 11
Number of Products under Development for Benign Prostatic Hyperplasia - Comparative Analysis, H2 2014 12
Number of Products under Development by Companies, H2 2014 14
Number of Products under Development by Companies, H2 2014 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2014 16
Comparative Analysis by Late Stage Development, H2 2014 17
Comparative Analysis by Clinical Stage Development, H2 2014 18
Comparative Analysis by Early Stage Development, H2 2014 19
Products under Development by Companies, H2 2014 20
Products under Investigation by Universities/Institutes, H2 2014 21
Benign Prostatic Hyperplasia - Pipeline by Euroscreen S.A., H2 2014 22
Benign Prostatic Hyperplasia - Pipeline by Aphios Corporation, H2 2014 23
Benign Prostatic Hyperplasia - Pipeline by Astellas Pharma Inc., H2 2014 24
Benign Prostatic Hyperplasia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2014 25
Benign Prostatic Hyperplasia - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2014 26
Benign Prostatic Hyperplasia - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 27
Benign Prostatic Hyperplasia - Pipeline by SK Chemicals Co., Ltd., H2 2014 28
Benign Prostatic Hyperplasia - Pipeline by Addex Therapeutics Ltd, H2 2014 29
Benign Prostatic Hyperplasia - Pipeline by AEterna Zentaris Inc., H2 2014 30
Benign Prostatic Hyperplasia - Pipeline by IntelGenx Corp., H2 2014 31
Benign Prostatic Hyperplasia - Pipeline by Kaken Pharmaceutical Co., Ltd., H2 2014 32
Benign Prostatic Hyperplasia - Pipeline by Nymox Pharmaceutical Corporation, H2 2014 33
Benign Prostatic Hyperplasia - Pipeline by Yungjin Pharm Ind. Co., Ltd., H2 2014 34
Benign Prostatic Hyperplasia - Pipeline by Quest PharmaTech Inc., H2 2014 35
Benign Prostatic Hyperplasia - Pipeline by Sophiris Bio, Inc., H2 2014 36
Benign Prostatic Hyperplasia - Pipeline by AndroScience Corporation, H2 2014 37
Benign Prostatic Hyperplasia - Pipeline by AmVac AG, H2 2014 38
Benign Prostatic Hyperplasia - Pipeline by KAEL-GemVax Co., Ltd., H2 2014 39
Benign Prostatic Hyperplasia - Pipeline by Ausio Pharmaceuticals, LLC, H2 2014 40
Benign Prostatic Hyperplasia - Pipeline by Biolab Sanus Farmaceutica Ltda., H2 2014 41
Benign Prostatic Hyperplasia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2014 42
Benign Prostatic Hyperplasia - Pipeline by SOM Biotech SL, H2 2014 43
Benign Prostatic Hyperplasia - Pipeline by Curadis GmbH, H2 2014 44
Benign Prostatic Hyperplasia - Pipeline by Mezzion Pharma Co. Ltd., H2 2014 45
Assessment by Monotherapy Products, H2 2014 46
Assessment by Combination Products, H2 2014 47
Number of Products by Stage and Target, H2 2014 50
Number of Products by Stage and Mechanism of Action, H2 2014 53
Number of Products by Stage and Route of Administration, H2 2014 55
Number of Products by Stage and Molecule Type, H2 2014 57
Benign Prostatic Hyperplasia Therapeutics - Recent Pipeline Updates, H2 2014 96
Benign Prostatic Hyperplasia - Dormant Projects, H2 2014 112
Benign Prostatic Hyperplasia - Discontinued Products, H2 2014 113